Nicoli Elena-Raluca, Huebecker Mylene, Smith David, Morris Lauren, Platt Frances M
Department of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK.
Wellcome Open Res. 2017 Aug 31;2:76. doi: 10.12688/wellcomeopenres.12431.2. eCollection 2017.
Niemann-Pick disease type C (NPC) disease is a neurodegenerative lysosomal storage disease caused by mutations in the or genes. Liver disease is also a common feature of NPC that can present as cholestatic jaundice in the neonatal period. Liver enzymes can remain elevated above the normal range in some patients as they age. We recently reported suppression of the P450 detoxification system in a mouse model of NPC disease and in post-mortem liver from NPC patients. As bile acids regulate the P450 system, we tested bile acid treatment using ursodeoxycholic acid (UDCA; 3α, 7β-dihydroxy-5β-cholanic acid), a hydrophilic bile acid, which is used to treat several cholestatic disorders. In this study, we compared UDCA treatment with the bile acid cholic acid (CA), and found unexpected hepatotoxicity in response to CA in Npc1 mice, but not to UDCA, suggesting that only UDCA should be used as an adjunctive therapy in NPC patients.
尼曼-匹克C型(NPC)病是一种神经退行性溶酶体贮积病,由 或 基因的突变引起。肝脏疾病也是NPC的常见特征,在新生儿期可表现为胆汁淤积性黄疸。随着一些患者年龄增长,其肝酶水平可能持续高于正常范围。我们最近报道了在NPC病小鼠模型和NPC患者的尸检肝脏中P450解毒系统受到抑制。由于胆汁酸调节P450系统,我们使用熊去氧胆酸(UDCA;3α,7β-二羟基-5β-胆烷酸)进行了胆汁酸治疗试验,UDCA是一种亲水性胆汁酸,用于治疗多种胆汁淤积性疾病。在本研究中,我们将UDCA治疗与胆汁酸胆酸(CA)治疗进行了比较,发现Npc1小鼠对CA有意外的肝毒性反应,而对UDCA没有,这表明在NPC患者中仅应使用UDCA作为辅助治疗。